Richard Jones

Q: What is Richard Jones email address?

Email Richard Jones at richard.jones@mdanderson.org. This email is the most updated Richard Jones email found in 2026.

Q: How to contact Richard Jones?

To contact Richard Jones send an email to richard.jones@mdanderson.org.

Co-Founder & Consultant at Asylia Therapeutics | Houston, Texas, United States

About Richard Jones

Richard Jones is a distinguished Co-Founder and Consultant at Asylia Therapeutics, Inc., where he leverages his extensive expertise in biologics research and development to spearhead innovative therapeutic solutions. With a deep-seated commitment to advancing first-in-class antibody therapeutics, Richard has played a pivotal role in the development of the company’s proprietary platform, which focuses on immune modulation for a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

At Asylia, Richard has been instrumental in the licensing of the anti-HSP70 IgG, a groundbreaking therapeutic candidate initially developed at MD Anderson. This strategic move underscores his ability to translate scientific research into viable clinical applications. His work is characterized by a robust drug pipeline that aims to enhance antigen presentation to the immune system, a critical mechanism for effective immunotherapy.

Richard's expertise extends beyond antibody therapeutics; he is also well-versed in small molecule inhibitor generation and evaluation, making him a versatile asset in drug discovery and development. His extensive background in scientific project management has allowed him to successfully navigate complex research initiatives, ensuring timely delivery of results. Furthermore, Richard is recognized as a subject matter expert in various fields, including Epstein Barr Virus biology and herpes virus virology, and is frequently sought after for presentations and publications in leading scientific forums. His exceptional network of medical and scientific colleagues further amplifies his influence in the biotechnology sector, positioning him as a key player in the quest for novel therapeutic interventions.

Richard Jones Work